Lymphoma Clinical Trial
Official title:
The Prevalence and the Prognostic Value of Sarcopenia Among Patients With Haematological Cancer Diseases - A Prospective Observational Cohort Study.
PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.
Status | Recruiting |
Enrollment | 216 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: • Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet. Exclusion Criteria: - Age: <18 - Pregnancy - Physical or mental disabilities precluding test of muscle function - Inability to read and understand Danish. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Whole body Lean body Mass | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 months after treatment start | |
Secondary | Hospitalization duration | Total number days in hospital | 1 year post treatment | |
Secondary | Disease free survival | Risk of disease progression | 1 year post treatment | |
Secondary | Overall survival | Risk of mortality from any-cause | 1 year post treatment | |
Secondary | Change in appendicular lean mass | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 after treatment start | |
Secondary | Change in whole body fat percentage | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 months after treatment start | |
Secondary | Change in visceral fat mass | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 months after treatment start | |
Secondary | Change in bone mineral density | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 months after treatment start | |
Secondary | Change in bone mineral content | Dual-energy X-ray Absorptiometry (DXA) scan | Baseline and 6 months after treatment start | |
Secondary | Change in walking capacity | Maximum 10 meter walking speed | Baseline and 6 months after treatment start | |
Secondary | Change in lower body physical function | 30 seconds Sit-To-Stand test | Baseline and 6 months after treatment start | |
Secondary | Change in maximum leg power | Leg extensor power test (Nottingham Power Rig) | Baseline and 6 months after treatment start | |
Secondary | Change in hand grip strength | Maximum strength test by handgrip dynamometer | Baseline and 6 months after treatment start | |
Secondary | Change in inflammation markers | Blood values are registered from the patients hospital record in relation to assessments. C-reactive protein (CRP) and leucocytes are registered as they are inflammation markers. | Baseline and 6 months after treatment start | |
Secondary | Change in creatinine | Blood values are registered from the patients hospital record in relation to assessments. Creatinine is registered due to their relation to muscle strength.. | Baseline and 6 months after treatment start | |
Secondary | Change in hemoglobin | Blood values are registered from the patients hospital record in relation to assessments. Hemoglobin is registered due to their relation to muscle strength. | Baseline and 6 months after treatment start | |
Secondary | Change in body fat percentage | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in fat mass | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in fat-free mass | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in muscle mass | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in bone mass | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in total body water | Bioelectrical Impedance Analyzer | Baseline and 6 months after treatment start | |
Secondary | Change in health-related quality of life | European Organisation for Research and Treatment of Cancer Quality of LifeQuestionnaire, Version 3.0 Scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. | Baseline and 6 months after treatment start | |
Secondary | Change in physical activity level | The International Physical Activity Questionnaires, short form. The Questionnaires covers the frequency and duration of vigorous, moderate, and walking activities over the last 7 days, as well as a single-item question on weekday sitting. Using the instrument's scoring protocol, total weekly physical activity can be calculated to three levels of physical activity and the interpretation of the questionnaire can be categorized in low, moderate and high physical activity, based on the stated time and Metabolic Equivalent of Task (METs min/week) used in different types of activities. | Baseline and 6 months after treatment start |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |